LONDON: Arix Bioscience plc, a global venture capital company focused on investing in and building breakthrough biotech companies, notes that its portfolio company Atox Bio, announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for reltecimod. The proposed indication is for the treatment of suspected organ dysfunction or…